EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study.

ABSTRACT:

Background

LUAD patients with EGFR exon 20 insertions (ex20ins) have a poorer prognosis than those with EGFR 19del or L858R mutations. The FAVOUR study showed high-dose furmonertinib's efficacy in ex20ins patients. However, more real-world data are needed to validate these findings.

Methods

We summarized LUAD patients who underwent NGS testing at Henan Cancer Hospital from January 1, 2020, to December 31, 2022. We then reviewed cases of patients with EGFR exon 20 insertion (ex20ins) mutations who received high-dose furmonertinib (240 mg/day) and had follow-up data. We assessed the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), time to treatment failure (TTF), overall survival (OS), and treatment-related adverse events (TRAEs).

SUBMITTER: Yang S 

PROVIDER: S-EPMC12090673 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature